Despite the large number of clinical trials conducted in recent years addressed to Helicobacter pylori and non-ulcer dyspepsia debate, no significant advances were made and both with and without encouraging information regarding the benefit of symptom relief after the eradicating regimen. After favourable experience with the Maastricht treatment, which has been recognised as the most promising in patients with non-ulcer dyspepsia we administrated to 90 patients one-week PPI-s based therapy with clarithromycin 2 × 250 mg and metronidazole 2 × 500 mg. All three PPI-s – lansoprazole 2 × 30 mg, omeprazole 2 × 20 mg and pantoprazole 2 × 40 mg – were tested for symptom relief, eradication rate, histological changes of antral mucosa and tolerance of therapy. 90 patients were divided into three subgroups ŕ 30 patients. In the first subset of patients treated with the lansoprazole based regim the eradication rate was 80 % with 30 % occurrence of adverse effects. In the second and third subsets of patients treated with omeprazole and pantop- razole based therapy the eradication rate was 87 and 83 % respectively with 17 % of adverse effects in both subgroups. The average eradication rate was 83.3 % and no statistical difference between three PPI-s based therapy were recorded (p = 0.05). The symptom relief in 6 days in 83.3 % and improvement of grading of chronic gastritis in 81.2 % of patients without significant differences in all three subsets (p = 0.05) showed efficacy of eradication therapy in patients with non-ulcer dyspepsia.

        Key words: Helicobacter pylori eradication – non-ulcer dyspepsia – proton pump inhibitors – adverse effects